These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 26424177)

  • 1. Pharmacokinetic and Pharmacodynamic Properties of Anti-VEGF Drugs After Intravitreal Injection.
    Semeraro F; Morescalchi F; Duse S; Gambicorti E; Cancarini A; Costagliola C
    Curr Drug Metab; 2015; 16(7):572-84. PubMed ID: 26424177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye).
    Stewart MW; Rosenfeld PJ; Penha FM; Wang F; Yehoshua Z; Bueno-Lopez E; Lopez PF
    Retina; 2012 Mar; 32(3):434-57. PubMed ID: 22374154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease.
    Tolentino M
    Surv Ophthalmol; 2011; 56(2):95-113. PubMed ID: 21335144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravitreal anti-VEGF therapy blocks inflammatory cell infiltration and re-entry into the circulation in retinal angiogenesis.
    Nakao S; Arima M; Ishikawa K; Kohno R; Kawahara S; Miyazaki M; Yoshida S; Enaida H; Hafezi-Moghadam A; Kono T; Ishibashi T
    Invest Ophthalmol Vis Sci; 2012 Jun; 53(7):4323-8. PubMed ID: 22661475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and complications of intravitreal injections performed in an Asian population in Singapore.
    Xu Y; Tan CS
    Int Ophthalmol; 2017 Apr; 37(2):325-332. PubMed ID: 27236451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological drug therapy for ocular angiogenesis: Anti-VEGF agents and novel strategies based on nanotechnology.
    Formica ML; Awde Alfonso HG; Palma SD
    Pharmacol Res Perspect; 2021 Apr; 9(2):e00723. PubMed ID: 33694304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES).
    Wu L; Martínez-Castellanos MA; Quiroz-Mercado H; Arevalo JF; Berrocal MH; Farah ME; Maia M; Roca JA; Rodriguez FJ;
    Graefes Arch Clin Exp Ophthalmol; 2008 Jan; 246(1):81-7. PubMed ID: 17674014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The expanding role of vascular endothelial growth factor inhibitors in ophthalmology.
    Stewart MW
    Mayo Clin Proc; 2012 Jan; 87(1):77-88. PubMed ID: 22212972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB.
    Avery RL; Castellarin AA; Steinle NC; Dhoot DS; Pieramici DJ; See R; Couvillion S; Nasir MA; Rabena MD; Maia M; Van Everen S; Le K; Hanley WD
    Retina; 2017 Oct; 37(10):1847-1858. PubMed ID: 28106709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravitreal anti-vascular endothelial growth factor therapy for choroidal neovascularization secondary to ocular histoplasmosis syndrome.
    Nielsen JS; Fick TA; Saggau DD; Barnes CH
    Retina; 2012 Mar; 32(3):468-72. PubMed ID: 21817958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration: an overview.
    Semeraro F; Morescalchi F; Duse S; Gambicorti E; Romano MR; Costagliola C
    Expert Opin Drug Saf; 2014 Jun; 13(6):785-802. PubMed ID: 24809388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biological, preclinical and clinical characteristics of inhibitors of vascular endothelial growth factors.
    Chong V
    Ophthalmologica; 2012; 227 Suppl 1():2-10. PubMed ID: 22517120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
    Sankar MJ; Sankar J; Mehta M; Bhat V; Srinivasan R
    Cochrane Database Syst Rev; 2016; 2():CD009734. PubMed ID: 26932750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antivascular endothelial growth factors in age-related macular degeneration.
    Schmidt-Erfurth U; Pollreisz A; Mitsch C; Bolz M
    Dev Ophthalmol; 2010; 46():21-38. PubMed ID: 20703030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema.
    Zehetner C; Kirchmair R; Huber S; Kralinger MT; Kieselbach GF
    Br J Ophthalmol; 2013 Apr; 97(4):454-9. PubMed ID: 23385630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel model of persistent retinal neovascularization for the development of sustained anti-VEGF therapies.
    Li Y; Busoy JM; Zaman BAA; Tan QSW; Tan GSW; Barathi VA; Cheung N; Wei JJ; Hunziker W; Hong W; Wong TY; Cheung CMG
    Exp Eye Res; 2018 Sep; 174():98-106. PubMed ID: 29852133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravitreal ranibizumab and bevacizumab therapy for choroidal neovascularization in age-related macular degeneration with extensive pre-existing geographic atrophy.
    Amaro MH; Roller AB
    Arq Bras Oftalmol; 2012; 75(4):273-6. PubMed ID: 23258660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravitreal anti-vascular endothelial growth factor for choroidal neovascularization secondary to pathologic myopia: systematic review and meta-analysis.
    Wang E; Chen Y
    Retina; 2013; 33(7):1375-92. PubMed ID: 23514793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Results of an expert survey on VEGF inhibitors in ophthalmology].
    Kühn T
    Klin Monbl Augenheilkd; 2011 Jul; 228(7):607-12. PubMed ID: 21472638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retinal function and morphology in rabbit after intravitreal injection of VEGF inhibitors.
    Myers AC; Lövestam Adrian M; Bruun A; Ghosh F; Andréasson S; Ponjavic V
    Curr Eye Res; 2012 May; 37(5):399-407. PubMed ID: 22510009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.